| Literature DB >> 24194763 |
Elizabeth A Frankman1, Marianna Alperin, Gary Sutkin, Leslie Meyn, Halina M Zyczynski.
Abstract
Objective. To determine frequency, rate, and risk factors associated with mesh exposure in women undergoing transvaginal prolapse repair with polypropylene mesh. Methods. Retrospective chart review was performed for all women who underwent Prolift Pelvic Floor Repair System (Gynecare, Somerville, NJ) between September 2005 and September 2008. Multivariable logistic regression was performed to identify risk factors for mesh exposure. Results. 201 women underwent Prolift. Mesh exposure occurred in 12% (24/201). Median time to mesh exposure was 62 days (range: 10-372). When mesh was placed in the anterior compartment, the frequency of mesh exposure was higher than that when mesh was placed in the posterior compartment (8.7% versus 2.9%, P = 0.04). Independent risk factors for mesh exposure were diabetes (AOR = 7.7, 95% CI 1.6-37.6; P = 0.01) and surgeon (AOR = 7.3, 95% CI 1.9-28.6; P = 0.004). Conclusion. Women with diabetes have a 7-fold increased risk for mesh exposure after transvaginal prolapse repair using Prolift. The variable rate of mesh exposure amongst surgeons may be related to technique. The anterior vaginal wall may be at higher risk of mesh exposure as compared to the posterior vaginal wall.Entities:
Year: 2013 PMID: 24194763 PMCID: PMC3782123 DOI: 10.1155/2013/926313
Source DB: PubMed Journal: Obstet Gynecol Int ISSN: 1687-9597
Selected demographic, clinical, and surgical variables (N = 201).
| Characteristic | Mesh exposure | No mesh exposure |
|
|---|---|---|---|
| Age (years)* | 67.3 ± 8.8 | 66.1 ± 8.1 | 0.49 |
| Body Mass Index (kg/m2)* | 28.2 ± 4.0 | 27.9 ± 5.0 | 0.78 |
| Smoking status | 0.30 | ||
| Nonsmoker | 14/23 (61%) | 119/173 (69%) | |
| Current smoker | 2/23 (9%) | 6/173 (3%) | |
| History of smoking | 7/23 (30%) | 48/173 (28%) | |
| Medical comorbidities | |||
| Diabetes | 4/23 (17%) | 7/164 (4%) | 0.03 |
| Hypertension | 12/24 (50%) | 99/175 (57%) | 0.66 |
| Surgical history | |||
| Prior incontinence procedure | 2/24 (8%) | 34/174 (20%) | 0.26 |
| Prior prolapse procedure | 6/24 (25%) | 53/176 (30%) | 0.81 |
| Prior hysterectomy | 12/24 (50%) | 111/177 (63%) | 0.27 |
| POPQ measurements | |||
| Preoperative Ba (cm)* | +3.0 ± 3.0 | +2.3 ± 2.6 | 0.23 |
| Preoperative Bp (cm)* | +0.9 ± 3.7 | +0.7 ± 3.1 | 0.81 |
| Preoperative C (cm)* | −0.7 ± 5.0 | −1.7 ± 4.4 | 0.30 |
| Preoperative TVL (cm)* | 8.6 ± 1.2 | 8.5 ± 2.2 | 0.77 |
| Surgical variables | |||
| Concomitant hysterectomy | 2/24 (8%) | 17/176 (10%) | >0.99 |
| EBL (ccs)* | 171 ± 194 | 140 ± 101 | 0.45 |
| Δ hemoglobin (preoperative – postoperative in g)* | 2.9 ± 1.2 | 2.4 ± 1.1 | 0.05 |
*Mean ± SD.
Management and outcomes of mesh exposure (N = 24).
| Estrogen cream alone ( | Mesh excision in the office* ( | Mesh excision in operating room* ( | Mesh excision in operating room and office* ( | |
|---|---|---|---|---|
| Resolved | 3 | 2 | 3 | 4 |
| Not resolved | 2 | 4 | 1 | 0 |
| Unknown† | 1 | 3 | 1 | 0 |
*All patients undergoing office and/or operating room mesh excision also used estrogen cream.
†No speculum examination since mesh exposure documented or since excision.